<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90903">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151253</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00028116</org_study_id>
    <nct_id>NCT02151253</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as
      a means of improving residual daytime sleepiness in patients with treated nocturia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale</measure>
    <time_frame>Week 2, Week 4, of each phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Epworth score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions, change in severity of excessive daytime sleepiness (EDS)</measure>
    <time_frame>Week 2, week 4, of each phase</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of naps</measure>
    <time_frame>Baseline; week 4 of each phase.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of minutes napped based on sleep diary</measure>
    <time_frame>Baseline; week 4 of each phase.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nocturia</condition>
  <condition>Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil 50 - 250 mg pills</intervention_name>
    <arm_group_label>Armodafinil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Receiving standard-of-care therapy for nocturia based on assessment by study
             physician

          2. Evaluation by study physician indicates that the patient meets criteria for either
             overactive bladder diagnosis, or nocturnal polyuria diagnosis.

          3. Mean number of nocturia episodes at least 2 per night based on day sleep/bladder
             diary

          4. Epworth Sleepiness Scale Score of at least 10

          5. Clinical Global Impression of Sleepiness at least Moderate

          6. Age 18-90 years inclusive

        Exclusion Criteria:

          1. Medications affecting urinary or sleep-wake function other than therapy for OAB o or
             NP within 5 half-lives of baseline assessment

          2. Sleep disorders other than nocturia based on history and screening assessment

          3. Unstable medical or psychiatry conditions

          4. Medical or psychiatric conditions affecting sleep/wake or urologic function

          5. Apnea-Hypopnea Index (AHI) ≥ 15 on screening polysomnogram

          6. Periodic Leg Movement Arousal Index (PLMAI) ≥ 15 on screening polysomnogram

          7. History of substance abuse or dependence in the last year

          8. Regular consumption of over 800 mg of caffeine use

          9. Shift-work in the 3 months prior to or during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Krystal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Bridgers</last_name>
      <phone>919-684-0752</phone>
      <email>jenny.bridgers@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Mayo</last_name>
      <phone>919-681-8392</phone>
      <email>mark.mayo@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew D Krystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nocturia</keyword>
  <keyword>Daytime sleepiness</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
